It's important to understand that "onset of action" can mean different things: feeling initial effects, seeing measurable weight loss, or reaching a stable maintenance dose.
Execution Summary: Key Timelines
● Initial Physiological Effects: Begin to appear within hours to days after the first dose.
● Significant Weight Loss (4-6%): Usually visible within the first 12 weeks.
● Significant Weight Loss (10-15% or more): Achieved during a treatment period of 36 to 48 weeks.
● Complete Efficacy: Achieved after dose escalation, approximately ****
○ Weight Loss: Best results were shown during the complete 48-week treatment period in the TRIUMPH study.
○ Glycemic Control: Significant improvement can be seen within weeks, but complete stabilization takes months.
Detailed Phased Timeline
Retatroptide is a once-weekly injection medication that requires a dose escalation phase. Start with a low dose to minimize side effects, then gradually increase to a maintenance dose over several months.
Phase 1: Initial Effects (First few days to weeks)
●Mechanism of Action: Immediately after the first injection, the drug begins to activate receptors (GIP, GLP-1, and glucagon) that regulate appetite and blood sugar.
●You may notice:
○Reduced Hunger: You may feel full faster and experience less craving for food.
○Increased Satiety: Postprandial satiety lasts longer.
○Early Side Effects: Some patients may experience nausea, vomiting, or diarrhea as their bodies adapt to the drug. Therefore, starting with a low dose is crucial.
●Conclusion: The drug begins to "work" at hormonal levels almost immediately, but physiological effects such as weight loss take longer to appear.
Phase 2: Early Measurable Results (Week 4 to Week 12)
●Mechanism of Action: As the body gradually adapts, the dosage is gradually increased (e.g., from 2 mg to 4 mg, then to 6 mg), and the effects on appetite suppression and calorie intake become more pronounced.
● Clinical Data: In the Phase 2 trial, after 12 weeks, participants taking a moderate dose of retatrutide lost an average of approximately 6% of their body weight, while the placebo group lost an average of approximately 1%.
● Conclusion: During this period, you and others may begin to notice a significant change in the numbers on the scale and how well your clothes fit.
Phase 3: Significant Weight Loss (Weeks 12 to 48)
● Treatment Process: The dose is continuously increased to a higher maintenance dose (e.g., 8 mg, 10 mg, 12 mg). This maximizes the drug's effectiveness.
● Clinical Data: This is the part of the trial where the most significant results were achieved:
○ At week 24, participants taking the highest dose (12 mg) lost an average of approximately 17% of their body weight.
○ At the end of the 48-week trial, those taking the 12 mg dose lost an average of 24% of their body weight.
● Conclusion: Most of the weight loss occurred during the period of maintaining a higher, stable dose. Throughout the treatment, weight loss remained effective.
Phase Four: Maintenance Phase (Week 48 and beyond)
●Treatment Process: Once the target maintenance dose is reached, patients will continue taking that dose indefinitely to maintain weight loss. The current trial has been extended to 104 weeks to investigate its long-term efficacy and safety.
●Conclusion: Retatrutide is designed for long-term use to maintain efficacy, similar to medications for chronic conditions such as hypertension.
Factors Affecting Onset of Action
●Starting Dose and Elevation Schedule: This is the most important factor and is managed by the physician.
●Individual Metabolism: The rate at which the body processes the drug.
●Diet and Lifestyle: The drug works best when combined with a low-calorie diet and increased physical activity. Without these changes, the effect will be slower.
●Individual Biological Differences: Each person's body responds slightly differently to the drug.
Whatsapp: ＋85246360786
sararaws128@gmail.com